Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Last Name

profileVictor H. Gerbaudo, Ph.D.

TitleAssistant Professor of Radiology
InstitutionBrigham and Women's Hospital
AddressBrigham and Women's Hospital
Nuclear Medicine
75 Francis St
Boston MA 02115
vCardDownload vCard (login for email)
Profile Picture

Collapse Biography 
Collapse awards and honors
2000Madame Curie Radiologic Science Lecturer
2001Partners in Excellence Award in Leadership and Innovation
2003Radiology Department Team Award
2004Award of Merit, American Roentgen Ray Society
20043rd Place, Best Paper of the Year Award, SNM
2007Partners in Excellence Team Award: Cyclotron Project
2008Partners in Excellence Team Award: Shapiro Cardiovascular Center Working Group
2008Partners in Excellence Team Award: Electronic Signature Project
2012Cum Laude Award, Radiological Society of North America
2013One of 3 Best Papers of the Year Award, SNM
2014Opening Plenary Speaker, World Federation of Nuclear Medicine & Biology Congress

Collapse Overview 
Collapse overview
Dr Gerbaudo is the Senior Director of Nuclear Medicine, Molecular Imaging and Noninvasive Cardiovascular Imaging Administration, and the Associate Scientific Director of the Advanced Multimodality Image Guided Operating Suite (AMIGO) in the Department of Radiology at the Brigham and Women’s Hospital, Harvard Medical School. He is a clinical Nuclear Oncology scientist with more than 20 years of experience in the field. His clinical, teaching and research efforts focus on the in-vivo qualitative and quantitative monitoring of tumor biology, imaging, and response to therapy with PET/CT.

Specific Academic Interests:
• Molecular biomarkers as predictors of clinical outcome in cancer patients
• Correlation between molecular biomarkers and medical imaging signatures
• PET Imaging-based phenotyping of thoracic malignancies
• Molecular imaging as a biomarker to non-invasively direct and monitor response to cancer therapy

Teaching Interests:
Gerbaudo's teaching integrates the application of basic concepts of tumor pathophysiology and molecular pathology to oncologic imaging, and to the interpretation and integration of imaging results into management decisions. Gerbaudo teaches Oncologic Nuclear Medicine, including both the clinical use of Gamma and Positron imaging (PET). Topics of interest include molecular imaging of tumor cell proliferation, perfusion, hypoxia and glycolytic metabolism. His audience is comprised of physician specialists, medical students, residents, research and clinical postdoctoral fellows, doctoral students, and technologists. His teaching topics include: 1) the application of basic concepts of tumor pathophysiology and molecular pathology to Oncologic imaging; 2) the review of the basic aspects of imaging instrumentation, and radiotracers used in Nuclear Oncology; 4) interpretation of imaging findings and their contribution to risk-adapted therapy and drug design; 5) the imaging and quantification of relevant tumoral processes such as proliferation, hypoxia, apoptosis and metabolism with PET/CT, and 6) research methodology, journal club, and the preparation of scholarly publication material.

Clinical and Research Interests:
Gerbaudo's clinical interests focus on the assessment and characterization of tumor invasion and metastasis with positron imaging of thoracic malignancies (i.e., malignant pleural mesothelioma, lung cancer), as well as esophageal cancer, brain and gastrointestinal tumors. His work in this area has expanded the use of clinical PET/CT for metabolically guided tumor biopsy and ablation, and for metabolic grading and staging of human tumors, as it relates to histological grade, molecular pathology, surgical stage and survival.
As a health care administrator, he is responsible for the overall operational effectiveness, patient experience, and financial health of the Brigham and Women’s Hospital Molecular Imaging service (Nuclear Medicine & PET, Radiopharmacy, Biomedical Imaging Core, AMIGO PET/CT), and of its Noninvasive Cardiovascular Imaging Program and the Cardiac Stress laboratory.

Gerbaudo's research activities include: 1) the anatomo-metabolic assessment of tumor aggressiveness in Malignant Pleural Mesothelioma, lung cancer, esophageal cancer and other thoracic tumors; 2) FDG and FLT imaging for the quantitative in-vivo functional characterization of tumor invasion and metastasis, and for the assessment of response early during the course of cancer therapy; 3) the study of the underlying molecular mechanisms associated with changes in dynamic properties of different PET probes with disease progression, and with the effect of chemotherapy on brain metabolism; 4) the use of PET/CT imaging for biopsy targeting in order to decrease sampling errors, for guiding tumor ablation, and to improve the accuracy of gross tumor volume definition during radiotherapy planning, and 5) in-vivo anatomo-metabolic tumor volume estimation as it relates to histological grade, proliferative potential, molecular pathology, surgical stage, response to cytotoxic and cytostatic therapies, and to survival.

o Nuclear Medicine Imaging Science, Nuclear Medicine Physics and Instrumentation,
Radioimmunoassay and Radiotracers, Los Angeles City College with clinical rotations at Holy
Cross Medical Center, VA West Los Angeles Medical Center and UCLA Medical Center, 1983
o Health Sciences, University of Redlands, 1984
o Clinical Nuclear Medicine and PET Imaging Science, UCLA School of Medicine, 1994
o Medicine, University of Buenos Aires School of Medicine, Argentina, 1995-1999
o Nuclear Oncology and Therapy, University of Miami School of Medicine, 2000
o Health Care Administration, University of Maryland University College, 2012

Collapse Bibliographic 
Collapse selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Zukotynski K, Gerbaudo VH, Kim CK. SPECT/CT in Neoplastic Disease. In Kim CK and Zukotynski K CK, editors. SPECT and SPECT/CT: a clinical guide. Thieme Publishers. 2017.
  2. Gerbaudo VH, Kim CK. PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet? Nucl Med Mol Imaging. 2017 Mar; 51(1):3-10. PMID: 28250852.
    View in: PubMed
  3. Zukotynski KA, Gerbaudo VH. Molecular Imaging and Precision Medicine in Lung Cancer. PET Clin. 2017 Jan; 12(1):53-62. PMID: 27863566.
    View in: PubMed
  4. Gerbaudo VH, Garcia CA . PET/CT of Lung Cancer. In Schoepf UJ & Meinel F. Multidetector-Row CT of the Thorax, 2nd ed. Springer International. 2016.
  5. Shim H, Joo J, Choi HJ, Hyun H, Gerbaudo VH, Kim CK. Lack of Increased FDG Uptake in the Lacrimal and Salivary Glands in Patients With Sarcoidosis and Potential Underlying Mechanism. Clin Nucl Med. 2016 Apr; 41(4):274-7. PMID: 26825201.
    View in: PubMed
  6. Choi HJ, Shim H, Hyun H, Gerbaudo VH, Kim CK. FDG PET/CT Appearance of Radiation Nephritis. Clin Nucl Med. 2016 Mar; 41(3):253-4. PMID: 26562578.
    View in: PubMed
  7. Barbone D, Follo C, Echeverry N, Gerbaudo VH, Klabatsa A, Bueno R, Felley-Bosco E, Broaddus VC. Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models. PLoS One. 2015; 10(8):e0134825. PMID: 26284517; PMCID: PMC4540424.
  8. Zukotynski KA, Kim CK, Gerbaudo VH, Hainer J, Taplin ME, Kantoff P, den Abbeele AD, Seltzer S, Sweeney CJ. (18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. Am J Nucl Med Mol Imaging. 2015; 5(1):72-82. PMID: 25625029; PMCID: PMC4299771.
  9. Horky LL, Gerbaudo VH, Zaitsev A, Plesniak W, Hainer J, Govindarajulu U, Kikinis R, Dietrich J. Systemic chemotherapy decreases brain glucose metabolism. Ann Clin Transl Neurol. 2014 Oct; 1(10):788-98. PMID: 25493270; PMCID: PMC4241806.
  10. Araki T, Sholl LM, Gerbaudo VH, Hatabu H, Nishino M. Thymic measurements in pathologically proven normal thymus and thymic hyperplasia: intraobserver and interobserver variabilities. Acad Radiol. 2014 Jun; 21(6):733-42. PMID: 24809315; PMCID: PMC4022310.
  11. Park M, Gerbaudo V, Hamberg L, Seaver K, Kijewski M. SU-D-9A-04: Brain PET/CT Imaging On a Scanner with a Large Axial Field-Of-View. Med Phys. 2014 Jun; 41(6):122-123. PMID: 28037596.
    View in: PubMed
  12. Sun Y, Gu X, Zhang E, Park MA, Pereira AM, Wang S, Morrison T, Li C, Blenis J, Gerbaudo VH, Henske EP, Yu JJ. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells. Cell Death Dis. 2014 May 15; 5:e1231. PMID: 24832603; PMCID: PMC4047866.
  13. Araki T, Sholl LM, Gerbaudo VH, Hatabu H, Nishino M. Intrathymic cyst: clinical and radiological features in surgically resected cases. Clin Radiol. 2014 Jul; 69(7):732-8. PMID: 24824976; PMCID: PMC4068340.
  14. Araki T, Sholl LM, Gerbaudo VH, Hatabu H, Nishino M. Imaging characteristics of pathologically proven thymic hyperplasia: identifying features that can differentiate true from lymphoid hyperplasia. AJR Am J Roentgenol. 2014 Mar; 202(3):471-8. PMID: 24555583; PMCID: PMC4020512.
  15. Wachsmann JW, Gerbaudo VH. Thorax: normal and benign pathologic patterns in FDG-PET/CT imaging. PET Clin. 2014 Apr; 9(2):147-68. PMID: 25030279.
    View in: PubMed
  16. Cervo M, Gerbaudo VH, Park MA, Moore SC. Quantitative simultaneous 111In/99mTc SPECT-CT of osteomyelitis. Med Phys. 2013 Aug; 40(8):082501. PMID: 23927346; PMCID: PMC3716783.
  17. Wada K, Gerbaudo VH, Spector M. Effects of PDGF-BB and OP-1 on mesenchymal stem cells in a porous mineral block. Int J Periodontics Restorative Dent. 2013 Mar-Apr; 33(2):e72-8. PMID: 23484183.
    View in: PubMed
  18. Etchebehere E, Gerbaudo VH, Nuñez R, Obando A, Paez D, Sen I. . Guide on Clinical Standard Operating Procedures on the use of PET/CT: A Practical Approach for Use in Adult Oncology. International Atomic Energy Agency, Department of Nuclear Sciences and Applications, Division of Human Health, Nuclear Medicine Section; . 2013.
  19. Gerbaudo VH . Mesotelioma Maligno. In Soriano Castrejon A, Comin M & Garcia Vicente AM, editors. Medicina Nuclear en la Práctica Clínica, 2nd edition,. 2012.
  20. Schleipman AR, Gerbaudo VH. Occupational radiation dosimetry assessment using an automated infusion device for positron-emitting radiotracers. J Nucl Med Technol. 2012 Dec; 40(4):244-8. PMID: 23024340.
    View in: PubMed
  21. Donohoe KJ, Agrawal G, Frey KA, Gerbaudo VH, Mariani G, Nagel JS, Shulkin BL, Stabin MG, Stokes MK. SNM practice guideline for brain death scintigraphy 2.0. J Nucl Med Technol. 2012 Sep; 40(3):198-203. PMID: 22743146.
    View in: PubMed
  22. Ikuta I, Sodickson A, Wasser EJ, Warden GI, Gerbaudo VH, Khorasani R. Exposing exposure: enhancing patient safety through automated data mining of nuclear medicine reports for quality assurance and organ dose monitoring. Radiology. 2012 Aug; 264(2):406-13. PMID: 22627599; PMCID: PMC3401350.
  23. Gill RR, Richards WG, Yeap BY, Matsuoka S, Wolf AS, Gerbaudo VH, Bueno R, Sugarbaker DJ, Hatabu H. Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume. AJR Am J Roentgenol. 2012 Feb; 198(2):359-63. PMID: 22268178.
    View in: PubMed
  24. Tatli, S, Gerbaudo VH, Silverman S. PET/CT Guided Interventions. In Gerbaudo VH , editor. A Case-Based Approach to PET/CT in Oncology. Cambridge University Press. 2012.
  25. Gerbaudo VH. Lung and Pleural Malignancies. In: Gerbaudo VH, editor. A Case-Based Approach to PET/CT in Oncology. Cambridge University Press. 2012.
  26. Gerbaudo VH & Gill, R. Esophageal Cancer. In Gerbaudo VH , editor. A Case-Based Approach to PET/CT in Oncology. Cambridge University Press. 2012.
  27. Gerbaudo VH, Editor. A Case-Based Approach to PET/CT in Oncology. Cambridge University Press. 2012.
  28. Britz-Cunningham S, & Gerbaudo VH. Functional Anatomy of the FDG Image. In: Gerbaudo VH, editor. A Case-Based Approach to PET/CT in Oncology. Cambridge University Press. 2012.
  29. Killoran JH, Gerbaudo VH, Mamede M, Ionascu D, Park SJ, Berbeco R. Motion artifacts occurring at the lung/diaphragm interface using 4D CT attenuation correction of 4D PET scans. J Appl Clin Med Phys. 2011 Nov 15; 12(4):3502. PMID: 22089005.
    View in: PubMed
  30. Nowak AK, Francis RJ, Katz SI, Gerbaudo VH. A Multimodality Imaging Review of Malignant Pleural Mesothelioma Response Assessment. PET Clin. 2011 Jul; 6(3):299-311. PMID: 27156725.
    View in: PubMed
  31. Gerbaudo VH, Katz SI, Nowak AK, Francis RJ. Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging. PET Clin. 2011 Jul; 6(3):275-97. PMID: 27156724.
    View in: PubMed
  32. Tatli S, Gerbaudo VH, Feeley CM, Shyn PB, Tuncali K, Silverman SG. PET/CT-guided percutaneous biopsy of abdominal masses: initial experience. J Vasc Interv Radiol. 2011 Apr; 22(4):507-14. PMID: 21367619.
    View in: PubMed
  33. Gerbaudo VH, Mamede M, Trotman-Dickenson B, Hatabu H, Sugarbaker DJ. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med Mol Imaging. 2011 May; 38(5):810-21. PMID: 21210110.
    View in: PubMed
  34. Gerbaudo VH and Jacobson F. PET/CT of Lung Cancer. In Van Den Abbeele, A.D. & Donahue K. Teaching Atlas of Nuclear Medicine. 2nd ed . Thieme Publishers. 2011.
  35. Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol. 2011 May; 103(1):137-46. PMID: 20838854.
    View in: PubMed
  36. Tatli S, Gerbaudo VH, Mamede M, Tuncali K, Shyn PB, Silverman SG. Abdominal masses sampled at PET/CT-guided percutaneous biopsy: initial experience with registration of prior PET/CT images. Radiology. 2010 Jul; 256(1):305-11. PMID: 20574103.
    View in: PubMed
  37. Gerbaudo VH, Britz-Cunningham S. Primary lesions were more 18F-FDG avid in patients with distant spread than in those without extensive disease. Mol Imaging Biol. 2009 Nov-Dec; 11(6):487; author reply 488. PMID: 19845044.
    View in: PubMed
  38. Schleipman AR, Gallagher PW, Gerbaudo VH. Optimizing safety of selective internal radiation therapy (SIRT) of hepatic tumors with 90Y resin microspheres: a systematic approach to preparation and radiometric procedures. Health Phys. 2009 Feb; 96(2 Suppl):S16-21. PMID: 19125051.
    View in: PubMed
  39. Gill RR, Gerbaudo VH, Sugarbaker DJ, Hatabu H. Current trends in radiologic management of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009; 21(2):111-20. PMID: 19822282.
    View in: PubMed
  40. Britz-Cunningham SH, Millstine JW, Gerbaudo VH. Improved discrimination of benign and malignant lesions on FDG PET/CT, using comparative activity ratios to brain, basal ganglia, or cerebellum. Clin Nucl Med. 2008 Oct; 33(10):681-7. PMID: 18806567.
    View in: PubMed
  41. Park SJ, Ionascu D, Killoran J, Mamede M, Gerbaudo VH, Chin L, Berbeco R. Evaluation of the combined effects of target size, respiratory motion and background activity on 3D and 4D PET/CT images. Phys Med Biol. 2008 Jul 07; 53(13):3661-79. PMID: 18562782.
    View in: PubMed
  42. Gill RR, Gerbaudo VH, Jacobson FL, Trotman-Dickenson B, Matsuoka S, Hunsaker A, Sugarbaker DJ, Hatabu H. MR imaging of benign and malignant pleural disease. Magn Reson Imaging Clin N Am. 2008 May; 16(2):319-39, x. PMID: 18474335.
    View in: PubMed
  43. Mamede M, El Fakhri G, Abreu-e-Lima P, Gandler W, Nosé V, Gerbaudo VH. Pre-operative estimation of esophageal tumor metabolic length in FDG-PET images with surgical pathology confirmation. Ann Nucl Med. 2007 Dec; 21(10):553-62. PMID: 18092131.
    View in: PubMed
  44. Zhu X, Park MA, Gerbaudo VH, Moore SC. Quantitative simultaneous In-111/Tc-99m planar imaging in a long-bone infection phantom. Phys Med Biol. 2007 Dec 21; 52(24):7353-65. PMID: 18065843.
    View in: PubMed
  45. Yamamuro M, Gerbaudo VH, Gill RR, Jacobson FL, Sugarbaker DJ, Hatabu H. Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol. 2007 Dec; 64(3):356-66. PMID: 17954021.
    View in: PubMed
  46. Gerbaudo VH, Julius B. Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging. Eur J Radiol. 2007 Dec; 64(3):401-5. PMID: 17870274.
    View in: PubMed
  47. Mamede M, Abreu-E-Lima P, Oliva MR, Nosé V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol. 2007 Aug; 30(4):377-88. PMID: 17762438.
    View in: PubMed
  48. Parysow O, Mollerach AM, Jager V, Racioppi S, San Roman J, Gerbaudo VH. Low-dose oral propranolol could reduce brown adipose tissue F-18 FDG uptake in patients undergoing PET scans. Clin Nucl Med. 2007 May; 32(5):351-7. PMID: 17452860.
    View in: PubMed
  49. Gerbaudo VH. Functional Anatomy of Tumor Aggressiveness in Lung Cancer and Malignant Pleural Mesothelioma. Molecular Imaging and Biology. 2005; 7:86.
  50. Wang H, Gerbaudo VH, Hobbs LW, Spector M. Quantitation of osteoblast-like cell mineralization on tissue culture polystyrene and Ti-6Al-4V alloy disks by Tc-99m-MDP labeling and imaging in vitro. Bone. 2005 Jan; 36(1):84-92. PMID: 15664006.
    View in: PubMed
  51. Schleipman AR, Gerbaudo VH, Castronovo FP. Radiation disaster response: preparation and simulation experience at an academic medical center. J Nucl Med Technol. 2004 Mar; 32(1):22-7. PMID: 14990671.
    View in: PubMed
  52. Rajadhyaksha CD, Parker JA, Barbaras L, Gerbaudo VH. Normal and Benign Pathologic Findings in 18-FDG-PET and PET/CT. Harvard Medical School Joint Program in Nuclear Medicine. 2004.
  53. Moore, SC, Park M, El Fakhri G, Gerbaudo VH, Zimmerman RE. A General-Spectral Method for Improved Quantitative SPECT Imaging of In-111. Nuclear Science Symposium Conference Record, IEEE. 2004; 6:3682-3684.
  54. Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, Treves ST. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax. 2003 Dec; 58(12):1077-82. PMID: 14645979; PMCID: PMC1746546.
  55. Gerbaudo VH. 18F-FDG imaging of malignant pleural mesothelioma: scientiam impendere vero... Nucl Med Commun. 2003 Jun; 24(6):609-14. PMID: 12766595.
    View in: PubMed
  56. Donohoe KJ, Frey KA, Gerbaudo VH, Mariani G, Nagel JS, Shulkin B. Procedure guideline for brain death scintigraphy. J Nucl Med. 2003 May; 44(5):846-51. PMID: 12732688.
    View in: PubMed
  57. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S, Di Carli MF, Mauceri C, Treves ST. Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med. 2002 Sep; 43(9):1144-9. PMID: 12215551.
    View in: PubMed
  58. Di Carli MF, Gerbaudo VH, Singh TP, Treves ST. Cardiopulmonary Studies in Pediatric Nuclear Medicine . In: Sandler MP, Coleman RE and Patton JA, editors. Diagnostic Nuclear Medicine . 2002.
  59. Di Carli M, Czernin J, Hoh CK, Gerbaudo VH, Brunken RC, Huang SC, Phelps ME, Schelbert HR. Relation among stenosis severity, myocardial blood flow, and flow reserve in patients with coronary artery disease. Circulation. 1995 Apr 01; 91(7):1944-51. PMID: 7895351.
    View in: PubMed
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at For faculty personal and demographic information, contact HMS Office for Faculty Affairs at
Gerbaudo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
Co-Authors Expand Description
Similar People Expand Description
Same Department Expand Description
Physical Neighbors Expand Description